Ebola in the DRC and Washington's travel paradox

The Democratic Republic of Congo is battling what the WHO declared a Public Health Emergency of International Concern on May 17, 2026 — a new Ebola outbreak in the Ituri region for which no currently approved drug exists. The outbreak has now claimed a second American casualty: a US national infected in the DRC has been medevaced to Berlin for treatment, following the first case transferred weeks earlier. The Trump administration’s response to both infections has been to block American citizens in the DRC from boarding commercial flights to the United States, while simultaneously funding a record-breaking treatment trial launched just six weeks after the PHEIC declaration — the fastest rollout of an experimental Ebola drug trial in history. The apparent contradiction — spending resources on a cure while abandoning citizens in the field — defines the political problem at the heart of Washington’s pandemic response architecture.

The received wisdom

Public health advocates and Democratic lawmakers have made the case that blocking American citizens from returning home is not only legally questionable but epidemiologically counterproductive. The argument runs as follows: citizens stranded in an active outbreak zone without consular support, unable to access US-quality medical evacuation, are more likely to become infected — and when they do, they will require the very expensive military medevac the travel block was presumably designed to avoid. Advocates also note that a travel ban on US citizens — as distinct from a visa restriction on foreign nationals — is unprecedented in modern American public health law and raises serious Fourth and Fifth Amendment questions about the right to return. Beyond the legalism: the optics of the richest country in the world abandoning its own citizens in a haemorrhagic fever zone, while simultaneously airlifting some of them to Berlin on military aircraft, makes a mockery of “America First” as a coherent doctrine.

A different read

The liberal critique lands some genuine blows, but it is worth interrogating both the public health orthodoxy and the political dynamics more carefully.

On the legal question: the administration’s position — that commercial flight restrictions are a temporary biosafety measure, not an indefinite prohibition on return — has more legal foundation than critics allow. The CDC’s existing Public Health Service Act authority allows broad quarantine and travel regulation powers during declared emergencies; the Supreme Court has never categorically ruled that citizens have an absolute right to board any particular mode of transport during a PHEIC. The more honest complaint is not that the ban is unlawful but that it is unaccompanied by any coherent repatriation plan — which is a serious gap in policy execution, not a constitutional crisis.

On the epidemiological question, the critics are on stronger ground but still missing something. Ebola’s transmission dynamics are fundamentally different from airborne respiratory diseases: the virus requires direct contact with bodily fluids of a symptomatic individual. The 2014–2016 West Africa outbreak, which killed over 11,000 people and briefly exported cases to the US, Spain, and the UK, demonstrated that commercially-transported Ebola cases can spark secondary chains — Thomas Eric Duncan’s arrival in Dallas in 2014 infected two nurses before the chain was broken. The Trump administration’s advisers appear to have concluded that the risk-adjusted cost of a domestic secondary chain, set against the political cost of a “Ebola comes home” headline, justifies extraordinary measures even at the cost of stranding citizens. That calculation may be wrong in its risk weighting, but it is not irrational.

What is genuinely striking — and genuinely encouraging — is the speed of the treatment trial. Six weeks from PHEIC declaration to first patients enrolled in a randomised controlled trial is extraordinary; the 2014 outbreak took many months to reach equivalent trial infrastructure. The lesson of 2014 was that the international community waited too long, misread the exponential curve, and paid an enormous price. The fact that two drugs are already in trial — without an approved therapy in existence — suggests that post-COVID institutional memory has genuinely improved outbreak response machinery. This is a story about global health governance getting something measurably right, even as Washington gets the domestic politics embarrassingly wrong.

The deeper structural issue is one that neither party addresses adequately: the absence of a standing rapid-repatriation protocol for US citizens caught in declared disease emergencies. The Berlin medevac was improvised. A standing arrangement — pre-negotiated aircraft, decontamination facilities, quarantine accommodation — would cost a fraction of the political damage caused by the current chaos. Britain maintained exactly such a protocol during the 2014 outbreak, quietly and without fanfare. The comparison is not flattering to Washington.

The partisan temptation, for both sides, is to weaponize this: Democrats to use stranded citizens as a cudgel against Trump, Republicans to use the travel block as evidence of biosecurity seriousness. The actual story is more banal and more instructive: a serious public health emergency, a genuinely impressive scientific response, and a domestic political apparatus that has still not built the institutional infrastructure to handle the two simultaneously.

What to watch

Watch mortality and containment data from Ituri: if the treatment trial produces early efficacy signals — and there is reason for cautious optimism given the two drugs under study — it could change the entire political calculus around repatriation by reducing the case-fatality ratio to manageable levels. Watch whether any stranded American dies in-country: that event would trigger congressional hearings and potentially a court challenge to the travel block’s constitutionality. Watch WHO’s diplomatic posture: if Geneva begins pushing back against unilateral travel restrictions by major donor states, it will force a renegotiation of the current framework. And watch whether Berlin becomes the de facto US medevac hub — a striking symbol of European public health capacity quietly filling a vacuum that Washington created.

— J